Use of Dogs in the Mediation of Conservation Conflicts

Conflicts between wildlife and humans are of global importance and are increasing. These conflicts may negatively impact wildlife, humans, and other resources, primarily livestock. Human safety and economic well-being can be adversely impacted by depredation of livestock and perpetuation of wildlife-borne diseases in agricultural systems. Conversely, management approaches to mitigate these conflicts may employ primarily lethal control methods that can negatively impact wildlife populations of conservation importance. Dogs, principally livestock protection breeds, have been used for centuries in some cultures to protect livestock from predators. Dogs have also been used for a variety of other conservation-specific practices. Here we provide an overview of a chapter we developed on this topic for a book entitled Free-ranging Dogs and Wildlife Conservation, just released by Oxford University Press (2013). We will review past and current use of dogs for mediating wildlife-human conflict and highlight future areas of research that are needed to more effectively use dogs for mediating conservation conflicts

Self-healing UV curable acrylate coatings for wood finishing system, part 1: impact of the formulation on self-healing efficiency

ABSTRACT: In the wood flooring sector, good surface mechanical properties, such as abrasion and scratch resistance, are prerequisite. Surface wood protection is provided by finishing systems. Despite coating improvement, scratches formation on wood flooring is unavoidable. A new approach to increase service life is to confer the self-healing property to the finishing system. The most common coatings used for prefinished wood flooring are acrylate UV curable 100% solids coatings. They usually have good mechanical properties and high cross-linking density. The objective of this study was to develop and evaluate an intrinsic self-healing formulation, which is applicable to wood flooring. For this purpose, acrylate formulations were developed with monomers and oligomers carrying hydroxyl groups. To meet the requirements of wood application, hardness, and polymerization conversion of coatings were evaluated. König pendulum damping tests provide information on coating hardness and flexibility. Results around 80 oscillations is acceptable for UV curable wood sealer. The chemical composition was studied by FT-IR spectroscopy while dynamical mechanical analysis (DMA) was performed to determine glass transition temperature and cross-linking density. The self-healing behavior was evaluated by gloss and scratch depth measurements. The formulation’s composition impacted the hydrogen binding quantity, the conversion, the Tg and the cross-linking density. The (hydroxyethyl)methacrylate (HEMA) monomer provided self-healing and acrylated allophanate oligomer allowed self-healing and cross-linking. This study demonstrated that it is possible to combine high cross-linking density and self-healing property, using components with low steric hindrance

Témoignages de la Guerre des Gaules dans le bassin clermontois, nouveaux apports

La localisation de la Gergovia antique et des ouvrages du siège césarien est admise depuis plusieurs années, au moins au sein de la communauté scientifique. Une mission d’expertise conduite au milieu des années 1990 a en effet permis de valider le tracé d’une partie des fortifications tel qu’il avait été décrit à l’issue des recherches du Second Empire. La multiplication des interventions archéologiques dans ce secteur du bassin clermontois permet de préciser le tracé du dispositif militaire installé en 52 av. J.-C. La mise au jour de nouveaux vestiges immobiliers (fossés, sépulture humaine et ensevelissements de chevaux, tronçons de voies) et mobiliers (militaria tardo-républicains) permet en effet de mieux cerner l’emprise du champ de bataille. Elle conduit à formuler des hypothèses nouvelles quant au déroulement du siège de l’oppidum.The location of the ancient Gergovia and the Caesarian siege works has been known for several years, at least within the scientific community. An expert mission conducted in the mid-1990s has enabled the validation of the layout of some of the fortifications as were described in research at the end of the Second Empire.The proliferation of archaeological work in this area of the Clermont bassin has enabled us to specify the route of Caesar’s military configuration set up in front of Gergovia in 52 BC.The discovery of new property remains (ditches, human burials and horse burials, sections of track) and home furnishings (late-Republican militaria) makes it possible to better understand the influence of the battlefield and lead to the formulation of new hypotheses about the course of the siege of the oppidum

Témoignages de la Guerre des Gaules dans le bassin clermontois, nouveaux apports

La localisation de la Gergovia antique et des ouvrages du siège césarien est admise depuis plusieurs années, au moins au sein de la communauté scientifique. Une mission d’expertise conduite au milieu des années 1990 a en effet permis de valider le tracé d’une partie des fortifications tel qu’il avait été décrit à l’issue des recherches du Second Empire. La multiplication des interventions archéologiques dans ce secteur du bassin clermontois permet de préciser le tracé du dispositif militaire installé en 52 av. J.-C. La mise au jour de nouveaux vestiges immobiliers (fossés, sépulture humaine et ensevelissements de chevaux, tronçons de voies) et mobiliers (militaria tardo-républicains) permet en effet de mieux cerner l’emprise du champ de bataille. Elle conduit à formuler des hypothèses nouvelles quant au déroulement du siège de l’oppidum.The location of the ancient Gergovia and the Caesarian siege works has been known for several years, at least within the scientific community. An expert mission conducted in the mid-1990s has enabled the validation of the layout of some of the fortifications as were described in research at the end of the Second Empire.The proliferation of archaeological work in this area of the Clermont bassin has enabled us to specify the route of Caesar’s military configuration set up in front of Gergovia in 52 BC.The discovery of new property remains (ditches, human burials and horse burials, sections of track) and home furnishings (late-Republican militaria) makes it possible to better understand the influence of the battlefield and lead to the formulation of new hypotheses about the course of the siege of the oppidum

GPI 2.0: Performance Evaluation of the Wavefront Sensor's EMCCD

The Gemini Planet Imager (GPI) is a high contrast imaging instrument that aims to detect and characterize extrasolar planets. GPI is being upgraded to GPI 2.0, with several subsystems receiving a re-design to improve the instrument's contrast. To enable observations on fainter targets and increase stability on brighter ones, one of the upgrades is to the adaptive optics system. The current Shack-Hartmann wavefront sensor (WFS) is being replaced by a pyramid WFS with an low-noise electron multiplying CCD (EMCCD). EMCCDs are detectors capable of counting single photon events at high speed and high sensitivity. In this work, we characterize the performance of the HN\"u 240 EMCCD from N\"uv\"u Cameras, which was custom-built for GPI 2.0. The HN\"u 240 EMCCD's characteristics make it well suited for extreme AO: it has low dark current ($<$ 0.01 e-/pix/fr), low readout noise (0.1 e-/pix/fr at a gain of 5000), high quantum efficiency ( 90% at wavelengths from 600-800 nm; 70% from 800-900 nm), and fast readout (up to 3000 fps full frame). Here we present test results on the EMCCD's noise contributors, such as the readout noise, pixel-to-pixel variability and CCD bias. We also tested the linearity and EM gain calibration of the detector. All camera tests were conducted before its integration into the GPI 2.0 PWFS system.Comment: 16 pages, 14 figures. Conference Proceedings for AO4ELT7, held in June 2023 in Avignon, Franc

APOBEC3A Is a Specific Inhibitor of the Early Phases of HIV-1 Infection in Myeloid Cells

Myeloid cells play numerous roles in HIV-1 pathogenesis serving as a vehicle for viral spread and as a viral reservoir. Yet, cells of this lineage generally resist HIV-1 infection when compared to cells of other lineages, a phenomenon particularly acute during the early phases of infection. Here, we explore the role of APOBEC3A on these steps. APOBEC3A is a member of the APOBEC3 family that is highly expressed in myeloid cells, but so far lacks a known antiviral effect against retroviruses. Using ectopic expression of APOBEC3A in established cell lines and specific silencing in primary macrophages and dendritic cells, we demonstrate that the pool of APOBEC3A in target cells inhibits the early phases of HIV-1 infection and the spread of replication-competent R5-tropic HIV-1, specifically in cells of myeloid origins. In these cells, APOBEC3A affects the amount of vDNA synthesized over the course of infection. The susceptibility to the antiviral effect of APOBEC3A is conserved among primate lentiviruses, although the viral protein Vpx coded by members of the SIVSM/HIV-2 lineage provides partial protection from APOBEC3A during infection. Our results indicate that APOBEC3A is a previously unrecognized antiviral factor that targets primate lentiviruses specifically in myeloid cells and that acts during the early phases of infection directly in target cells. The findings presented here open up new venues on the role of APOBEC3A during HIV infection and pathogenesis, on the role of the cellular context in the regulation of the antiviral activities of members of the APOBEC3 family and more generally on the natural functions of APOBEC3A

Photography-based taxonomy is inadequate, unnecessary, and potentially harmful for biological sciences

The question whether taxonomic descriptions naming new animal species without type specimen(s) deposited in collections should be accepted for publication by scientific journals and allowed by the Code has already been discussed in Zootaxa (Dubois & Nemésio 2007; Donegan 2008, 2009; Nemésio 2009a–b; Dubois 2009; Gentile & Snell 2009; Minelli 2009; Cianferoni & Bartolozzi 2016; Amorim et al. 2016). This question was again raised in a letter supported by 35 signatories published in the journal Nature (Pape et al. 2016) on 15 September 2016. On 25 September 2016, the following rebuttal (strictly limited to 300 words as per the editorial rules of Nature) was submitted to Nature, which on 18 October 2016 refused to publish it. As we think this problem is a very important one for zoological taxonomy, this text is published here exactly as submitted to Nature, followed by the list of the 493 taxonomists and collection-based researchers who signed it in the short time span from 20 September to 6 October 2016

Re-visiting Meltsner: Policy Advice Systems and the Multi-Dimensional Nature of Professional Policy Analysis

10.2139/ssrn.15462511-2

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline